The BRAIN Foundation Industry Seed Investment in Jelikalite

The BRAIN Foundation is happy to announce our seed investment in JelikaLite for a total raise of $760,000 along with our co-investors.

JelikaLite is a medical technology company with a focus on neurological health in pediatric population using non-invasive therapies.

JelikaLite is developing developing a novel, non-invasive photobiomodulation device for improved communication and anxiety in autism. This device system, named Cognilum, combines a wearable near-infrared light therapy device that records physical measurements with an intelligent AI platform.

Cognilum provides personalization through data collection, analysis and reporting to improve a child’s autism symptoms.

Congratulations to JelikaLite for being accepted into the prestigious Mount Sinai Elementa program and for the successful completion of their second Phase I feasibility open study.

You can watch JelikaLite’s BRAIN Synchrony Symposium presentation and read more on their new and upcoming clinical trials on this page.